China Approves Additional Indication for Hengrui’s Remimazolam Injection
Jiangsu Hengrui Pharmaceuticals says China’s NMPA approved an additional indication for remimazolam tosilate for injection.
Related stories
Alphabet Shares Trigger Death Cross After Post-Earnings Slide
Alphabet shares entered bearish territory after a post-earnings skid. The report says shares rebounded after four of the past five death crosses over the last decade, with an avera
M impact | EQUITY | Oct 29, 2026, 07:10 PM UTC
CVC Acquires Stake in Recordati
CVC acquired shares in Recordati on October 29, 2026.
M impact | EQUITY | Oct 29, 2026, 07:09 PM UTC
Perella Weinberg Partners Reports Quarterly Results
Perella Weinberg Partners reported results for the quarter ended September 30.
M impact | EQUITY | Oct 29, 2026, 07:09 PM UTC
Polymarket Pauses Trading After $2.65 Million Exploit
Polymarket said it placed its exchange in cancel-only mode and paused relayer actions while investigating a compromise of a third-party provider. More than $2.6 million was lost wi
M impact | EQUITY | Oct 29, 2026, 07:01 PM UTC
A. O. Smith Reports Third-Quarter 2026 Revenue of $940.5 Million
Revenue fell 0.2% year over year to $940.5 million. Net income declined 4.3% to $126.3 million, while diluted EPS was $0.93 versus $0.94 a year earlier.
M impact | EQUITY | Oct 29, 2026, 07:01 PM UTC
Carrier Reports $2.59 Billion Third-Quarter Loss on $3.1 Billion Impairment
Carrier Global reported third-quarter 2026 revenue of $6.26 billion, up 12.3% year over year, and diluted EPS loss of $3.16. A $3.1 billion goodwill impairment was tied to weaker E
M impact | EQUITY | Oct 29, 2026, 07:01 PM UTC